newsfilter
← Latest News
GlobeNewswire·

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

- Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing